- Home
- WEN vs NAMS Comparison
WEN vs NAMS Comparison
Compare WEN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEN
- NAMS
- Stock Information
- Founded
- WEN 1969
- NAMS 2019
- Country
- WEN United States
- NAMS Netherlands
- Employees
- WEN N/A
- NAMS N/A
- Industry
- WEN Restaurants
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- WEN Consumer Discretionary
- NAMS Health Care
- Exchange
- WEN Nasdaq
- NAMS Nasdaq
- Market Cap
- WEN 2.3B
- NAMS 2.2B
- IPO Year
- WEN N/A
- NAMS N/A
- Fundamental
- Price
- WEN $11.40
- NAMS $18.11
- Analyst Decision
- WEN Hold
- NAMS Strong Buy
- Analyst Count
- WEN 18
- NAMS 6
- Target Price
- WEN $16.69
- NAMS $42.83
- AVG Volume (30 Days)
- WEN 5.0M
- NAMS 660.2K
- Earning Date
- WEN 05-02-2025
- NAMS 05-08-2025
- Dividend Yield
- WEN 7.80%
- NAMS N/A
- EPS Growth
- WEN N/A
- NAMS N/A
- EPS
- WEN 0.94
- NAMS N/A
- Revenue
- WEN $2,235,211,000.00
- NAMS $47,140,000.00
- Revenue This Year
- WEN N/A
- NAMS N/A
- Revenue Next Year
- WEN $4.14
- NAMS N/A
- P/E Ratio
- WEN $12.12
- NAMS N/A
- Revenue Growth
- WEN 2.18
- NAMS 586.97
- 52 Week Low
- WEN $10.98
- NAMS $14.06
- 52 Week High
- WEN $20.60
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- WEN 36.55
- NAMS 47.80
- Support Level
- WEN $11.16
- NAMS $16.79
- Resistance Level
- WEN $11.59
- NAMS $19.58
- Average True Range (ATR)
- WEN 0.31
- NAMS 0.94
- MACD
- WEN -0.02
- NAMS -0.12
- Stochastic Oscillator
- WEN 27.27
- NAMS 47.07
About WEN Wendy's Company (The)
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $12.6 billion in 2024, narrowly edging Burger King ($11.5 billion) and clocking in well behind wide-moat McDonald's ($51.1 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spanned more than 7,200 total stores in 30 countries as of year-end 2024. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for roughly 94% of stores, and through franchise flipping and advisory fees.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.